BSR_03_0038_A2_S89
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.540
- ALLOGRAFT_REJECTION+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- INFLAMMATORY_RESPONSE+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
- WNT_BETA_CATENIN_SIGNALING+0.420
- NOTCH_SIGNALING+0.380
- HEDGEHOG_SIGNALING+0.370
- KRAS_SIGNALING_UP+0.360
- TGF_BETA_SIGNALING+0.330
Top 10 suppressed
- E2F_TARGETS-0.580
- G2M_CHECKPOINT-0.490
- MYC_TARGETS_V2-0.490
- OXIDATIVE_PHOSPHORYLATION-0.420
- MTORC1_SIGNALING-0.410
- MYC_TARGETS_V1-0.400
- DNA_REPAIR-0.340
- BILE_ACID_METABOLISM-0.300
- FATTY_ACID_METABOLISM-0.270
- ADIPOGENESIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518138 | — | D | 0.936 |
| 2 | TCGA-A2-A25A-01A-12R-A16F-07 | — | A | 0.923 |
| 3 | R163 | — | — | 0.915 |
| 4 | ERR2278881 | — | — | 0.915 |
| 5 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.913 |
| 6 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.911 |
| 7 | TCGA-E2-A1IJ-01A-11R-A144-07 | — | A | 0.909 |
| 8 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.908 |
| 9 | TCGA-BH-A6R9-01A-21R-A32P-07 | — | A | 0.908 |
| 10 | MDT-AP-1201 | Med | Medulloblastoma | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |